Question 1 · Medium
Statements about CBNAAT: 1. It detects rifampicin resistance through rpoB mutations. 2. A positive result distinguishes live from dead bacilli. 3. It can be used on cerebrospinal fluid and lymph node aspirates. 4. It replaces culture for monitoring treatment response. Which combination is correct?
- A1 and 3 only
- B1 and 4 only
- C1, 2 and 3 only
- D2 and 4 only
Show answerHide answer
Answer: A · 1 and 3 only
The assay targets rpoB mutations for rifampicin resistance and is validated on several extrapulmonary specimens including cerebrospinal fluid and lymph node aspirates. It cannot distinguish viable from dead bacilli, so it stays positive during successful treatment and is unsuitable for monitoring, which uses smear and culture. Key point: CBNAAT detects rpoB mutations and works on extrapulmonary samples, but cannot monitor treatment.
- B: Statement 4 is wrong, though statement 1 is correct.
- C: Statement 2 is wrong: DNA from dead bacilli is also amplified.
- D: Statement 4 is wrong: monitoring uses smear and culture.